Hepatitis B virus (HBV) infection is a worldwide health concern that infects nearly 254 million people globally and causes more than 1 million deaths annually. The highest prevalence is seen in sub-Saharan Africa and the Western Pacific region. Cirrhosis, liver failure, and hepatocellular carcinoma (HCC) are reported a...
Uzair Iqbal, Khadijah Khalid, Y. Yukselten et al.· Biomolecules· 0 citations
C-C chemokine receptor type 5 (CCR5) is the primary co-receptor mediating the entry of R5-tropic human immunodeficiency virus type 1 (HIV-1) into CD4+ T cells and macrophages, making it one of the most promising therapeutic targets in HIV cure research. The naturally occurring CCR5Δ32 mutation which abolishes surface C...
Cancer immunotherapy has improved outcomes across many tumor types, but primary and acquired resistance, tumor heterogeneity and a shortage of safe targets remain unresolved. Part of this gap arises because tumor cells evade immune recognition not only through genomic mutation but also through post-transcriptional mRNA...
Y. Yukselten, Haseeb Ahmad, Mohammed Shoultout et al.· Frontiers in Immunology· 0 citations
It is demonstrated that a lead VTAC compound, VTAC-2, restores CoA levels to wild-type levels both in cells and in mouse brain, making this compound an attractive candidate for clinical evaluation for the treatment of PKAN.
Jessica Regan, A. Pal, S. Gihaz et al.· Journal of Biological Chemis...· 0 citations
The molecular mechanisms, preclinical evidence and emerging clinical data supporting CRISPR-based CCR5 disruption, including multiplex editing strategies designed to overcome viral tropism switching, and the evolving role of maraviroc beyond viral entry inhibition are examined.
